August 12, 2024
“CervoMed (CRVO) The first Morgan Stanley pick we’ll look at is CervoMed, a clinical-stage medical research firm specializing in neurodegenerative diseases and conditions… Overall, the analyst expects positive clinical results and rates CRVO an Overweight (i.e., Buy). His $35 price… Continue Reading…
March 29, 2024
“Viking Therapeutics shares closed more than 15% higher on Tuesday after the company said its experimental weight loss pill showed positive results in a small study and will enter the next stage of development later this year… Viking is one of several small… Continue Reading…
February 29, 2024
“Shares of Viking Therapeutics closed more than 120% higher on Tuesday after the company’s experimental weight loss drug showed promising initial results in a mid-stage trial. Viking Therapeutics is one of several small obesity drugmakers hoping to enter the budding weight loss drug industry, which analysts say… Continue Reading…
January 12, 2024
“…After rising in premarket trading, TGTX stock toppled 15.4% to 17.77 after the stock market opened… TGTX stock has been on an upswing after hitting a recent low at 6.46 in October. From that low point, TGTX stock has bounded 225% as… Continue Reading…
January 1, 2024
“Bristol Myers Squibb on Friday announced it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash, or $330 per share. Karuna’s stock closed up more than 47% on the news Friday, hitting $317.85 a share. Bristol Myers Squibb shares closed up 2%…”… Continue Reading…
November 30, 2022
“Cathie Wood, CEO and founder of Ark Invest, says she invests on a five-year time horizon, betting big on speculative growth names such as Tesla (TSLA), Roku (ROKU), Zoom Video Communications (ZM) and Shopify (SHOP). But in 2022 at least, Ark’s 10 biggest holdings are down sharply. 0… Continue Reading…
March 1, 2022
“…Enter billionaire Steven Cohen. The legendary stock picker, who began his investing career at Gruntal & Co. where he managed proprietary capital for 14 years, founded S.A.C Capital Advisors in 1992. In 2014, his investment operations were converted to Point72… Continue Reading…
March 31, 2021
“Savara, Inc. (SVRA)… Overall, SVRA has 3 recent analyst reviews, and all are Buys, making the analyst consensus rating a Strong Buy. The average price target stands tall at $4.67, which suggests the stock has room for 173% upside in the… Continue Reading…
March 9, 2021
“On24 (ONTF)… Sometimes, a company is just so solid and successful that Wall Street’s analysts line up right behind it – and that is the case here. The Strong Buy analyst consensus rating is unanimous, based on 8 Buy-side reviews published… Continue Reading…
January 6, 2021
“9 Meters Biopharma (NMTR)… Turning now to the rest of the Street, other analysts are on the same page. With 4 Buys and no Holds or Sells, the word on the Street is that NMTR is a Strong Buy. Given… Continue Reading…
Recent Comments